• français
    • English
  • français 
    • français
    • English
  • Connexion
JavaScript is disabled for your browser. Some features of this site may not work without it.
Accueil

Afficher

Cette collectionPar Date de CréationAuteursTitresSujetsNoms de revueToute la baseCentres de recherche & CollectionsPar Date de CréationAuteursTitresSujetsNoms de revue

Mon compte

Connexion

Statistiques

Afficher les statistiques d'usage

A Price Comparison Study of Recent Drugs in EU5, 2008-2012

Thumbnail
Date
2013
Indexation documentaire
Economie sociale
Subject
Drugs; prices
Code JEL
I.I1.I12
Nom de la revue
Value in Health
Volume
16
Numéro
7
Date de publication
11-2013
Pages article
A455
Nom de l'éditeur
Elsevier
DOI
http://dx.doi.org/10.1016/j.jval.2013.08.762
URI
https://basepub.dauphine.fr/handle/123456789/11981
Collections
  • LEDa : Publications
Métadonnées
Afficher la notice complète
Auteur
Le Pen, Claude
255365 Laboratoire d'Economie de Dauphine [LEDa]
Grandfils, N.
Vigier, D.
Type
Article accepté pour publication ou publié
Résumé en anglais
Objectives To compare prices of new drugs between France and the other EU4. Methods Study used IMS MIDAS database for economic data such as prices and sales volume and LEEM database (French association of the pharmaceutical manufacturers) for the ASMR scale (HAS assessment of the drug’s added value/innovation). All the products applying for the first time for reimbursement by the French Public health insurance between January 2008 and June 2012 were included in the study (except those restricted to hospital use in France) and having an ASMR rating and an official price in June 2012. Paasche and Laspeyres price-index were calculated for drugs with: a) high ASMR, b) ASMR IV, c) ASMR V and d) all drugs. A sensitivity analysis was conducted to measure the effect of different weighting options. Results A total of 107 products (245 dosages) were included in this study. Fifty-one (48%) have been found available in the community pharmacies of all the 5 countries. The availability analysis by pair of countries (France + another) is higher: 94 for Germany, 79 for UK, 71 for Spain and 69 for Italy (Italy often restricts drug’s access to hospitals only). French prices are generally equal to or lower than prices in the four other markets, which shows a relative price index decrease for France since 2008 studies. The only significant exception are UK prices for products ranked in France ASMR 1-2-3 (20% less expensive). Prices are regularly and significantly higher in Germany than in all other countries. Interestingly, the highest disparities in prices occur for the ones ranked as most innovative in France – while ASMR IV have surprisingly consistent prices across EU5. Conclusions European patients don’t have consistent access to the same drugs in retail market, and the drugs considered innovative in France show a large price index disparity across EU5, with UK prices being 20% lower.

  • Accueil Bibliothèque
  • Site de l'Université Paris-Dauphine
  • Contact
SCD Paris Dauphine - Place du Maréchal de Lattre de Tassigny 75775 Paris Cedex 16

 Cette création est mise à disposition sous un contrat Creative Commons.